Real-life analysis of biologics switching in CRSwNP

Introduction Three different biologics (Dupilumab, Omalizumab, Mepolizumab) are now approved in Germany for the therapy of uncontrolled, severe, chronic rhinosinusitis with nasal polyps (CRSwNP). Although our clinical experience also shows a high response rate, some patients experience insufficient treatment success. Since it is still unclear whether these patients benefit from switching to another biologic, we analyzed our clinical data in this regard.

Material and methods This is a preliminary, retrospective evaluation. Treatment outcome was assessed using the EPOS (Fokkens et al. Rhinology 2020) and EUFOREA recommendations (Bachert C, et al. J Allergy Clin Immun 2021). The following parameters were systematically collected: Nasal Polyp Score (NPS), questionnaires (Sinonasal Outcome Test (SNOT-22), Asthma Control Test (ACT)) and visual analog scales (VAS)), olfactory tests (Sniffin’sticks), blood eosinophilia.

Results Data from a total of 199 patients treated with biologics for CRSwNP in our clinic from June 2019 to November 2022 were included. During this period, 19 patients switched biologics. Values were compared at the time of switch, versus the last visit. After the switch, we observed an overall positive response with an average improvement in all parameters collected.

Summary Our current data suggest that switching biologics can lead to clinically meaningful treatment success.

Publication History

Article published online:
12 May 2023